Kuros Biosciences publishes study in Spine journal showing MagnetOs doubles fusion rate in posterolateral fusions compared to autograft, based on a 1-year follow-up of 91 patients.

Kuros Biosciences, a leading bone healing tech company, announced the publication of a peer-reviewed study in Spine journal. The MAXA Level 1 study outlines the effectiveness of MagnetOs in challenging posterolateral fusions (PLF) as a standalone alternative to autograft, with nearly double the fusion rate at 79% overall. The study included 91 patients and 128 segments with 1-year follow-up after surgery.